WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

SHANGHAI and AUSTIN, Texas, April 8, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.


In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the United States, China and other territories. In addition, he will play a key role in forging and maintaining strong connections between our customers and WuXi's business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.


Dr. Hausheer brings more than 30 years' experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.


"We're very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer," said Mr. Edward Hu, Co-CEO of WuXi AppTec. "Dr. Hausheer's rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi's clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world."


Prior to joining WuXi, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.


Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents.


About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com


Cision View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-appoints-dr-frederick-h-hausheer-as-chief-medical-officer-300825787.html

Related Links :

http://www.wuxiapptec.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【人才管理】社會撕裂 = 職場撕裂?HR提建議免影響工作情緒

    【經濟日報專訊】本港近期社會動盪,令部分人的憤怒及不滿情緒蔓延至職場,出現口角甚至暴力場面,嚴重影響人際關係及工作。

  • 【人才管理】打工仔批公司孤寒 「度縮」行徑逐個講

    【晴報專訊】不少僱主都要設法開源節流,但過分慳儉或惹員工不滿。有網民指,公司為了慳錢,只會「配給」文具。有公司每月只分派一卷廁紙給員工,如同事不夠用,便要向公司購買。

  • 【人才管理】老細對罷工4種態度 網民︰政治問題老細解決?

    為令政府回應有關《逃犯條例》修訂風波及近日示威活動的訴求,不少網民發起8月5日(今日)進行「三罷」(罷工、罷課、罷市)。

  • 【企業管理】港職場兩性未平等 女高層流失率高

    【經濟日報專訊】社會各企業逐漸提升兩性職場平等,包括促進領導層性別多元化、提升對女性領袖關注等。惟有調查報告指出,本港企業女性管理人員流失率偏高;當公司規模愈大,女高層的流失問題就愈嚴重。

  • 【職場辛酸史】素食餐廳禁員工食肉 如有發現立即解僱

    【晴報專訊】午休應為員工的自由時間,但如果連用餐類別都被老闆限制,大家又能否接受?

  • Tesla被爆環境惡劣 員工:如生產地獄

    美國電動車巨頭Tesla近日被員工爆料,指Tesla為達生產目標,要求員工在惡劣條件下工作,猶如「生產地獄」。

  • 因「道德」問題被炒? 有員工被大企秋後算帳離職

    【經濟日報專訊】Google作為全球頂尖企業,其開放的工作模式,令不少打工仔羨慕不已。但事實上,看似為員工帶來大量福利和津貼的背後,亦曾遭受大批員工罷工抗議。

  • 返工「尋開心」須集齊3大因素

    【晴報專訊】問你一個問題:「你在工作中找到快樂嗎?」你會如何回答?原來世上六成員工都答「否」。不開心的員工會為公司帶來成功嗎?研究和分析公司總裁米高布殊(Michael C. Bush)指,要員工快樂,不只是提供金錢和福利,亦取決於公司對待他們的方式。

  • Agoda、Booking.com、KAYAK邊個最好用?幕後老闆現身解說

    【經濟日報專訊】食、玩、買是港人放假的重點娛樂,加上近年廉航及網上預訂機票、酒店、行程平台發展迅速,一年去四次旅行,對港人來說已是平常事。

  • 美企進駐香港︰港專才不遜矽谷

    【經濟日報專訊】估值逾12億美元(約93億港元)的美國醫療保險公司Clover,今年初登陸堅尼地城一間共享工作間內。其主席兼首席技術總監蔡淙健(Andrew Toy)表示,香港將成為公司的技術中心,今年目標在港聘30名軟件工程師;其工程副總裁朱煒(David Zhu)亦在港坐鎮,同時負責發展國際技術夥伴關係。